
    
      Hepcortespenlisimut-L (V5) immunotherapy of HCC in an open label setting with baseline
      alphafetoprotein serum levels and CT scan image as primary endpoints with monthly follow-up
      thereafter. Additional endpoints will include blood biochemistry indices and safety
      monitoring.
    
  